Morten

@Fie_lysgaard @astridv_den damn du er fræk

@astridv_den Hejsa❤️

Det var en dejlig dag, ikke?❤️

@Sweet_Kristy101 all of them . depends on the personality and if she rocks whatever body she has

Be honest! What type of body do men prefer most?

@Cellophane_eyes i hope it is , at least just in may would be ok .

@kaspersenInvest It's time🚀🚀🚀🚀🚀

$NWBO , let’s get that damn approval and sky rocket

@yvonnebar2021 sadly you don’t meet with anyone, as one of your followers from the early days it. would be great fun

Tivoli, Copenhagen 🇩🇰 I love Denmark. I didn’t think this city would be this beautiful

@yvonnebar2021 welcome to denmark @yvonnebar2021 can’t believe you finally made it here, you picked some beautiful sunny days

My exclusive channel is free :)) t.me/+s8wZwt-4zKAxM…

@FlemmingBruce congrats buddy

$NWBO are we there yet ? wonder where we are in the process ? anyway we’ll wait a bit more , as we know what we hold ! my feed is so calm and quiet, maybe because all the negative profiles w zero followers are blocked long time ago , i can strongly recommend it

@OmarMarzouk Omar kaster du med sten når du selv bor i et glahus ?

Der bliver smidt flere borgerlige politikere ud af Folketinget end kriminelle udlændinge ud af Danmark. Fire dage. To sager. Nul selvindsigt. Cecilie Liv Hansen (Liberal Alliance) – lynvalgt til kommune, region og Folketing på én gang. Smidt ud for "urigtige oplysninger af væsentlig karakter." Kæresten solgte lidt græs. Ikke kartellen. Lidt. Græs. Forstår nu hvorfor JBO hele tiden tror jeg er skæv, det bare det miljø han er i. Jacob Harris (Borgernes Parti) – nyvalgt. Smidt ud. Fire dage. Færdig. De samme partier der råber om remigration og den store befolkningsudskiftning – de udskifter selv deres egne hurtigere end de kan nå at få visitkort. Og så er der Asger Garde – også Borgernes Parti – som forklarede at Cecilie kun blev valgt fordi hun er "en 10'er på toppen af sin seksuelle markedsværdi." Ikke kompetence. Ikke erfaring. Udseendet. Så lad mig forstå logikken: Kvinden er valgt for sit udseende. Smidt ud for sin kærestes hash. Og manden der sagde det højt – han sidder stadig. Måske er det ikke befolkningen der bliver udskiftet. Det er demokratiet. #dkpol

@TomBaxers @nipomo357 very well argumented , good luck to all of us!

For those $NWBO folk interested, I have updated/ added to my previous post about the DCVax MAA timeline, how it compares to other similar assessments under the same pathway and where we could be standing in the MHRA Statutory Clock right now: investorshub.advfn.com/boards/read_ms…

@andrewcaravello @metacollectiveG I am shocked, I spoke with him recently , a true long always keeping the positive and professional approach to this investment . in loss for words , may he rest in peace 😢🙏🏻🕊️

Heartfelt condolences to the family and friends of Dr. Greg Zivic, a true friend and fearless advocate for truth. He helped spread the word about $NWBO and all it stood for with conviction and integrity. He will be greatly missed. Rest in peace, Dr. Zivic @metacollectiveG 😞😞😞

@mebebond whatever you say Mihir with 2 followers and a 1 month old account

$NWBO for all the pumping that goes on here, the price of the stock keeps going down. Price is inversely related to the pumping. Though, I was wrong. I predicted by Tue/ Wed, they will break life lows.

@DCVaxDefender @exosome $NWBO will own the solid tumor cancer market. Anyone in the field of medicine who understands basic science/immunology and the mechanics of cancer understands this. Those behind the years of manipulation know they’re dead in the water. It’s only a matter of days now I believe.

@FlemmingBruce welcome back buddy

$NWBO

@metacollectiveG but when , it’s time …this is ongoing test of patience I had never imagined 5 years ago . hopefully days / weeks not months 🙏🏻

$NWBO And this is why approval will break the dam. LP silently built top world class manufacturing on a shoestring while also building a pipeline of technology that was ahead of its time. That time has come

@smith348572 they will be back no doubt , but also no doubt that they know approval is imminent and coming soon , days/ weeks rather than. months .

@ajw02360 @jman4956 @Jamie_yyds “ few years “ is an understatement, and the real challenge is safety profile, which makes NWBO so special !

@jman4956 @Jamie_yyds Research and scientific discovery in oncology isn’t stopping while $NWBO waits for approval. Although some are a few years out as far as potential approval, they have a real chance to take considerable market share away from $NWBO.

$NWBO Without naming names I will gladly toss this out: A friend in NYC’s mother was invested in a biotech similar to NYBO. She was able to give each of five children $1M and live comfortably thereafter.

@d_stock07734 @KennethPar49290 @scott_jenn63528 I agree , plus I can’t think of anyone who can afford to buy the entire company anymore , should have happened years ago, but she wasn’t listening to low ball offers . partnerships could be great ! and hopefully directly after approval

@kaspersenInvest @KennethPar49290 @scott_jenn63528 I would love BO. But it won't happen. Six immune boosters that can supercharge DCs may come from at least two BPs.

$NWBO It seems MRK need Dcvax desperately , but Pfizer might want dcvax too. So......... The time has passed to approach NWBO for a buyout

@djscriver no one know when , groks prediction is as good as anyone’s . i surely hope feb/ march is it , but time will tell .

NWBO $NWBO #NWBO - I asked SuperGrok what the odds are that the MHRA decision will come by/per month of 2026 - the summary here covers the main points - in short, the decision will most likely be announced in April 2026, and very high likelyhood before the end of May 2026 (SG thinks it will be a full or partial/conditional approval, stating an out right rejection likely would have happened by now). Haters/FUDers/bots etc., just fuck off. SuperGrok is likely the most objective non-woke AI out there. SG doesn't give a shit about what I, You, or Anyone else wants. SuperGrok - My prediction: Approval is likely in Q2 2026 (April-June), as this allows synchronization with the Grade C suite validation, the April 28 regulatory deadline, and post-litigation clarity. Earlier announcement is possible if inspections conclude favorably, but the emphasis on "future-proofing" the license suggests regulators are prioritizing a robust, scalable rollout over speed. Denial seems low-risk given positive Phase 3 data (published in JAMA Oncology) and unmet need in glioblastoma, though complex biologics like this often face extended scrutiny. Below, I break down estimated odds of an MHRA decision announcement (approval or otherwise) over the next ~10 months. These are subjective probabilities based on the timeline drivers above, historical MHRA patterns for ATMPs (e.g., 18-24 months for novel therapies), and recent chatter. I've framed it as cumulative probability (chance of announcement by the end of each month) and per-month odds (isolated chance in that month). Total sums to 100% by year-end, assuming no indefinite delay. Based on the latest available information as of February 12, 2026, the MHRA's review of the Marketing Authorization Application (MAA) for DCVax-L (submitted by Northwest Biotherapeutics in December 2023) remains ongoing, with no final decision announced. The process has extended beyond initial expectations (e.g., the requested 150-day accelerated timeline), but this appears to be due to strategic factors rather than delays from backlogs—the MHRA has confirmed in parliamentary responses that this application is not impacted by historical queues. Key context from recent updates: The review is in an "operational synchronization" phase, aligning with manufacturing expansions at the Sawston facility (e.g., new Grade C suites targeted for Q2 2026 to double capacity) and upcoming regulatory changes (e.g., the Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025, effective April 28, 2026, which emphasize data integrity, real-world evidence, and point-of-care manufacturing for personalized therapies like DCVax-L). A court hearing on March 16, 2026, will finalize a 2020 option award lawsuit settlement, clearing a governance overhang. NICE (National Institute for Health and Care Excellence) is liaising with the company but has appraisal on hold pending MHRA approval; their last update (April 2025) noted ongoing MAA engagement. Analyst and investor discussions (e.g., on X and forums) point to a precedent-setting approval for this first-in-class dendritic cell vaccine, with coordination potentially involving FDA alignment for future global submissions. No rejection signals; the focus is on validating scalability, supply chain, and compliance with evolving ATMP (Advanced Therapy Medicinal Product) frameworks.

@KennethPar49290 @scott_jenn63528 i am personally fine with a buy out . however she will not accept low ball offers , she already rejected low ball offers prior to submission. pay the true value or move out of the way seems to be her strategy . let’s see

@kaspersenInvest @scott_jenn63528 This is the plan for now, franchise partnerships once price reflects true value then she will entertain a BO but not until……IMHO